Tumour-associated neutrophils in patients with cancer

Shaul, Merav E.; Fridlender, Zvi G.

doi:10.1038/s41571-019-0222-4

Cited by 663 publications

(662 citation statements)

References 264 publications

Supporting

Mentioning

589

Contrasting

Order By: Relevance

“…For example, granulocyte colony-stimulating factor (G-CSF) is a primary regulator of neutrophil proliferation and differentiation and is often given to cancer patients to replenish the neutrophil population after chemotherapy-related neutropenia [43]. G-CSF mimetics are currently in clinical trial in combination with chemotherapy and could be considered for treatment of BM-PCa [44]. Although we did not examine the role of androgen deprivation therapy on neutrophil function in the prostate tumor-bone microenvironment, ongoing studies are examining the impact of standard of care BM-PCa therapies in the immune-bone microenvironment.…”

Section: Discussionmentioning

confidence: 99%

Neutrophils are mediators of metastatic prostate cancer progression in bone

Costanzo-Garvey

Keeley

Case

et al. 2020

Cancer Immunol Immunother

View full text Add to dashboard Cite

Bone metastatic prostate cancer (BM-PCa) significantly reduces overall patient survival and is currently incurable. Current standard immunotherapy showed promising results for PCa patients with metastatic, but less advanced, disease (i.e., fewer than 20 bone lesions) suggesting that PCa growth in bone contributes to response to immunotherapy. We found that: (1) PCa stimulates recruitment of neutrophils, the most abundant immune cell in bone, and (2) that neutrophils heavily infiltrate regions of prostate tumor in bone of BM-PCa patients. Based on these findings, we examined the impact of direct neutrophilprostate cancer interactions on prostate cancer growth. Bone marrow neutrophils directly induced apoptosis of PCa in vitro and in vivo, such that neutrophil depletion in bone metastasis models enhanced BM-PCa growth. Neutrophil-mediated PCa killing was found to be mediated by suppression of STAT5, a transcription factor shown to promote PCa progression. However, as the tumor progressed in bone over time, neutrophils from late-stage bone tumors failed to elicit cytotoxic effector responses to PCa. These findings are the first to demonstrate that bone-resident neutrophils inhibit PCa and that BM-PCa are able to progress via evasion of neutrophil-mediated killing. Enhancing neutrophil cytotoxicity in bone may present a novel therapeutic option for bone metastatic prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Neutrophils are mediators of metastatic prostate cancer progression in bone

Costanzo-Garvey

Keeley

Case

et al. 2020

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Bone marrow macrophages release G-CSF in response to uptake of returning neutrophils, which then stimulates the release of new neutrophils into the blood flow 7 . The essential contribution of living neutrophils and their subtypes in cancer and other diseases have been described in numerous reviews elsewhere [8][9][10] . Here, we focus on neutrophil cell death and the fundamental impact of its deregulation in chronic disease and cancer.…”

Section: Neutrophil Life Cyclementioning

confidence: 99%

The role of neutrophil death in chronic inflammation and cancer

2020

View full text Add to dashboard Cite

show abstract

“…As mentioned above, increased circulating neutrophils (NLR) are associated with poor outcome of treatment with TMZ in glioma patients (see Section 2). Moreover, in other cancer types, a growing body of evidence has demonstrated that TANs are associated with pro-tumor phenotypes and play a role in the development of chemotherapy resistance [27,28,63]. Thus, future experimental studies are warranted to investigate the role of TANs in the development of resistance against standard chemotherapy (TMZ) in GBM.…”

Section: Chemotherapy and Anti-vegf Therapy Resistancementioning

confidence: 99%

Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance

Khan

Mittal

McGee

et al. 2020

IJMS

View full text Add to dashboard Cite

Recent efforts in brain tumor research have been directed towards the modulation of the immune system for therapeutic interventions. Several human cancers, including gliomas, are infiltrated with immune cell types—including neutrophils and myeloid-derived suppressor cells—that contribute to tumor progression, invasiveness, and treatment resistance. The role of tumor-associated neutrophils and myeloid-derived suppressor cells in cancer biology remains elusive, as these cells can exert a multitude of pro-tumor and antitumor effects. In this review, we provide the current understanding and novel insights on the role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance, as well as the mechanisms of pleiotropic behaviors in these cells during disease progression, with an emphasis on possible strategies to reprogram these cells towards their antitumor actions.

show abstract

Tumour-associated neutrophils in patients with cancer

Cited by 663 publications

References 264 publications

Neutrophils are mediators of metastatic prostate cancer progression in bone

Neutrophils are mediators of metastatic prostate cancer progression in bone

The role of neutrophil death in chronic inflammation and cancer

Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance

Contact Info

Product

Resources

About